Clinical trial · Observational
Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer
Whether Controlling Serum Uric Acid (SUA) Can Benefit Postoperative Survival in Patients With Pancreatic Cancer
NCT07091526CI-TRIAL-00099331recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This retrospective study aims to analyze the impact of postoperative changes in serum uric acid (SUA) levels on the prognosis of patients undergoing pancreatic cancer resection.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Serum Uric Acid | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| serum uric acid test | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- High serum uric acid
- description
- The increase of after serum uric acid operation compared with that before operation is≥10% Normal levels serum uric acid are typically 178 to 360 μm (3 to 6.8 mg/dl).
- interventionNames
- Diagnostic Test: serum uric acid test
- label
- Low serum uric acid
- description
- The increase of after serum uric acid operation compared with that before operation \< 10% Normal serum uric acid levels are typically 178 to 360 μm (3 to 6.8 mg/dl).
- interventionNames
- Diagnostic Test: serum uric acid test
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 3-5 years
- description
- Overall survival was defined as the time from diagnosis to death.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with pathologically confirmed pancreatic cancer (primary) * Patients who underwent Radical resection of pancreatic cancer（Pancreaticoduodenectomy or Distal pancreatectomy） * The postoperative survival time was at least 6 weeks Exclusion Criteria: * No surgery was performed, or only palliative surgery/ biopsy was performed * Patients who underwent emergency hemodialysis or plasma exchange after surgery * History of gout or long-term urate-lowering therapy, such as allopurinol * Patients are missing follow-up data * Hydrochlorothiazide and furosemide were used * Chronic kidney disease * Oncolytic syndrome * Hemolytic anemia * Lead poisoning * Hyperparathyroidism * Hypothyroidism * A tyrosinase inhibitor was used * Patients with nonpancreatic primary tumors * Pregnant or postpartum women.
References
Publications (2)
- BACKGROUNDHuang CF, Huang JJ, Mi NN, Lin YY, He QS, Lu YW, Yue P, Bai B, Zhang JD, Zhang C, Cai T, Fu WK, Gao L, Li X, Yuan JQ, Meng WB. Associations between serum uric acid and hepatobiliary-pancreatic cancer: A cohort study. World J Gastroenterol. 2020 Nov 28;26(44):7061-7075. doi: 10.3748/wjg.v26.i44.7061. PMID 33311950
- BACKGROUNDFini MA, Elias A, Johnson RJ, Wright RM. Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med. 2012 Aug 15;1(1):16. doi: 10.1186/2001-1326-1-16. PMID 23369448